ESC 365 - Safety of discontinuing anticoagulation after atrial fibrillation ablation

ESC2025 Premium Access

Safety of discontinuing anticoagulation after atrial fibrillation ablation

Session: Anticoagulation in atrial fibrillation: one size doesn't fit all

Topic: Oral Anticoagulation

Speaker: Doctor R. Tripathi (Stony Brook, US)

Event: ESC Congress 2025

Congress Presentation

Add to my library

About the speaker

Doctor Rahul Tripathi

Stony Brook University Hospital, Stony Brook (United States of America)

1 presentation

0 follower

6 more presentations in this session

Anticoagulation strategy of choice for atrial fibrillation ablation - a network meta-analysis of complication rates

Speaker: Mr C. Ursu (Bucharest, RO)

Who missed out on anticoagulation? a nationwide temporal analysis of patients with new-onset atrial fibrillation and no anticoagulation

Speaker: Mr A. Luojus (Helsinki, FI)

Direct oral anticoagulants versus warfarin for atrial fibrillation in patients with transthyretin cardiac amyloidosis: a retrospective cohort analysis

Speaker: Doctor E. Habib (Phoenix, US)

Long-term real-world outcomes of edoxaban in atrial fibrillation patients with and without prior ischaemic stroke: A 4-year follow-up analysis from ETNA-AF Europe

Speaker: Professor R. De Caterina (Pisa, IT)

Interrupted or uninterrupted direct oral anticoagulants for atrial aibrillation ablation which is the best strategy insights from a network meta-analysis

Speaker: Mr O. Makdah (Cottbus, DE)

Access the full session

Anticoagulation in atrial fibrillation: one size doesn't fit all

Speakers: Doctor R. Tripathi, Mr C. Ursu, Mr A. Luojus, Doctor E. Habib, Professor R. De Caterina...

About the event

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress

ESC 365 is supported by

bristol-myers-squibb

Explore sponsored resources

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources